Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa). Although most patients initially respond to ADT, almost all cancers eventually develop castration resistance. Castration-resistant PCa (CRPC) is associated with a very poor prognosis, and the treatment of wh...

Full description

Bibliographic Details
Main Authors: Shangwei Zhong, Shoujiao Peng, Zihua Chen, Zhikang Chen, Jun-Li Luo
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Pharmaceutics
Subjects:
androgen deprivation therapy (ADT)
castration-resistant prostate cancer (CRPC)
kinase
kinase inhibitors
IκB kinase (IKK)
TANK-binding kinase 1 (TBK1)
Online Access:https://www.mdpi.com/1999-4923/14/3/498

Internet

https://www.mdpi.com/1999-4923/14/3/498

Similar Items